GHO Capital has sold VISUfarma, a specialty pharmaceutical provider, to Lupin Limited in a deal that expands the Indian company's European footprint. VISUfarma, formed in 2016 through the combination of founder-owned Italian VISUfarma and Nicox's European operations, offers over 60 branded products for conditions including dry eye, glaucoma, and retinal health.

Lupin Limited, headquartered in Mumbai, distributes pharmaceutical products across more than 100 global markets. The acquisition accelerates Lupin's specialty franchise buildout and is immediately accretive to earnings. VISUfarma's portfolio includes treatments for eyelid hygiene, blepharitis, and specialty nutraceuticals, strengthening Lupin's position in the European pharmaceutical market.

The transaction marks a significant move for Lupin as it seeks to bolster its specialty pharmaceutical offerings in Europe. With VISUfarma's established presence and diverse product range, the deal positions Lupin to better compete in the specialty pharmaceutical segment across European markets.